Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Position-5–driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape
Takeshi Nakama, Aaron Wall, Garry Dolton, Li Rong Tan, Hannah Thomas, Hiroshi Hamana, Yoshiki Aritsu, Toong Seng Tan, Mako Toyoda, Yoshihiko Goto, Huanyu Li, Mizuki Kitamatsu, Keiko Udaka, Yusuke Miyashita, Hiroyuki Oshiumi, Kimitoshi Nakamura, Yoji Nagasaki, Rumi Minami, Hirotomo Nakata, Pierre J. Rizkallah, Hiroyuki Kishi, Takamasa Ueno, Andrew K. Sewell, Chihiro Motozono
Takeshi Nakama, Aaron Wall, Garry Dolton, Li Rong Tan, Hannah Thomas, Hiroshi Hamana, Yoshiki Aritsu, Toong Seng Tan, Mako Toyoda, Yoshihiko Goto, Huanyu Li, Mizuki Kitamatsu, Keiko Udaka, Yusuke Miyashita, Hiroyuki Oshiumi, Kimitoshi Nakamura, Yoji Nagasaki, Rumi Minami, Hirotomo Nakata, Pierre J. Rizkallah, Hiroyuki Kishi, Takamasa Ueno, Andrew K. Sewell, Chihiro Motozono
View: Text | PDF
Research Article Immunology Infectious disease

Position-5–driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape

  • Text
  • PDF
Abstract

Cytotoxic T lymphocytes form a critical component of SARS-CoV-2 immunity by recognizing viral peptides bound to HLA class I molecules. Here, we identified the spike-derived peptide NYNYLYRLF448-456 (NF9) as the immunodominant HLA-A*24:02–restricted epitope in both convalescent and vaccinated donors. Across cohorts, A24/NF9-specific responses were dominated by public TCR motifs featuring TRAV12-1 paired with TRBJ2-7 and a conserved CDR3β sequence (CASSXXXGYEQYF). Using a panel of 13 TCRs, we mapped recognition of single amino acid substitutions within NF9 and identified residue 5 (L452) as the principal determinant of escape. The L452R substitution, characteristic of the Delta variant, abolished recognition across all tested TCRs despite preserved HLA binding. Crystallography of a representative public TCR (P1-15) revealed that mutation at position-5 reoriented the peptide within HLA-A*24:02, flipping the adjacent Y453 side chain into the peptide-binding groove and eliminating the dominant TCR contact. This position-5–driven conformational switch provided a structural mechanism for universal loss of NF9 recognition by HLA-A*24:02–restricted T cells. Consistent with this, Delta-infected convalescents failed to mount de novo NF9-5R–specific responses while retaining responses to the conserved A24/QI9 spike epitope. Together, these findings defined the basis of A24/NF9 recognition and showed how 1 mutation remodeled peptide presentation to abrogate TCR responses.

Authors

Takeshi Nakama, Aaron Wall, Garry Dolton, Li Rong Tan, Hannah Thomas, Hiroshi Hamana, Yoshiki Aritsu, Toong Seng Tan, Mako Toyoda, Yoshihiko Goto, Huanyu Li, Mizuki Kitamatsu, Keiko Udaka, Yusuke Miyashita, Hiroyuki Oshiumi, Kimitoshi Nakamura, Yoji Nagasaki, Rumi Minami, Hirotomo Nakata, Pierre J. Rizkallah, Hiroyuki Kishi, Takamasa Ueno, Andrew K. Sewell, Chihiro Motozono

×

Figure 7

NF9-5R–specific T cells are not detectable in SARS-CoV-2 Delta-infected convalescents.

Options: View larger image (or click on image) Download as PowerPoint
NF9-5R–specific T cells are not detectable in SARS-CoV-2 Delta-infected ...
(A) Activation-induced marker assay of PBMCs from vaccinated donors with no evidence of prior SARS-CoV-2 infection. Cells were stimulated for 14 days with A24/NF9 (NYNYLYRLF448–456) or A24/QI9 (QYIKWPWYI1208–1216) peptides. Data show the percentage of CD25+CD137+CD8+ T cells in HLA-A*24:02–negative (n = 4) and HLA-A*24:02+ (n = 8) donors. Wilcoxon matched-pairs signed-rank test (*P = 0.0156, **P = 0.0078). (B) Activation-induced marker assay of PBMCs from unvaccinated convalescents infected with the SARS-CoV-2 Delta variant. Cells were stimulated with A24/NF9, A24/NF9-5R, or A24/QI9 peptides. Data show the percentage of CD25+CD137+CD8+ T cells in HLA-A*24:02–negative (n = 9) and A*24:02+ (n = 8) donors. Wilcoxon matched-pairs signed-rank test (*P = 0.0391). (C) Ex vivo detection of HLA-A*24:02–restricted tetramer+ CD8+ T cells in Delta-infected convalescents. PBMCs from HLA-A*24:02–negative (n = 6) and A*24:02+ (n = 7) donors were stained with tetramers specific for HIV-KW9 (negative control), A24/NF9, A24/NF9-5R, or A24/QI9. Wilcoxon matched-pairs signed-rank test (*P = 0.0156 versus A24/HIV-KW9 and A24/NF9-5R and *P = 0.0312 versus A24/NF9).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts